

BIGGLAND
Hormonal therapy – Synthetic prostaglandin
Injectable use
case with 6 bottles of 2 ml
20 ml bottle
Composition: each 1 ml contains 75 μg of D(+)Cloprostenol, prostaglandin F2alpha synthetic analogue.
Indications:
Estrus synchronization: the synchronization of the estrous cycle helps to increase efficiency under certain operational conditions by allowing the correct estrus detection and facilitating the use of artificial insemination to achieve genetic improvements, through the use of superior bulls, while facilitating venereal disease control. It also helps to program service and calving seasons, seasoning deliveries, thus achieving better yields, greater weaning weight, and a larger proportion of cyclic cows at the beginning of the next service.
Therapeutic use:
Abortion induction: in the first half of gestation, for example in very young heifers.
Pyometra due to retention of the corpus luteum: in chronic endometritis with a possible bacterial infection, antibiotic therapy will be considered.
Expulsion of mummified fetuses: the administration of Biggland will be followed by a delivery process with subsequent expulsion of the mummified fetus.
Silent estrus: animals can be treated with Biggland after determining the presence of the corpus luteum by rectal palpation.
Farrowing induction in sows: shortening of farrowing time due to better dilation of the cervix and greater myometrium contractility, especially in multiple births.
Administration and dosage: by intramuscular (IM) route.
Therapeutic use:
Cattle: 2 ml (0,15 mg) per animal, administer in the neck or the hindquarters.
Sheep: 0,5 ml (0,038 mg) per animal, administer in the hindquarters.
Pigs: 1 ml (0,075 mg) per animal, administer in the neck or the hindquarters.
Estrus synchronization:
Cattle and sheep: 2 doses with an interval of 11 days, followed by two inseminations performed between 72 and 96 hours after the treatment. Normal fertility results after the second Biggland dose administration.
Administer according to professional criteria.
Precautions: do not administer to pregnant females if you do not want to induce abortion. It is recommended not to induce abortion in animals that have completed the first half of gestation.
Biggland is absorbed through the skin, thus pregnant women, asthmatics, and persons with bronchial or other respiratory problems must take extreme precautions when handling this product. Wash immediately with plenty of soap and water if accidental skin contact occurs. In the event of bronchospasm, immediately administer by inhalation route a rapid-acting bronchodilator such as isoprenaline or salbutamol. Seek medical advice.
Action: Biggland produces morphological and functional regression of the corpus luteum (luteolysis), followed by estrus return, with normal ovulation, 2 to 4 days after treatment. Please note that in the period from ovulation to the 5-7 posterior days, the animals are refractory to treatment as luteolytic effects of prostaglandins have not manifested yet. With a wide therapeutic index, Biggland does not alter fertility and no undesirable effects have been reported on offspring conceived after treatment.